ultimately it would vary and be dependent upon the disease/condition being treated...not to mention the number and severity of side effects for the drug.
However given the known side effects of Trof (which have been published during the trials as well as Acadia messaging) I feel 1/4 isnt as a bad a result as first impressions might be.
Ann: Q4 2023 quarterly activity report, page-7
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.23 |
Change
0.960(7.82%) |
Mkt cap ! $1.699B | |||
| Open | High | Low | Value | Volume |
| $12.95 | $13.36 | $12.79 | $6.410M | 491.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 650 | $13.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.25 | 632 | 4 |
View Market Depth
| Last trade - 14.11pm 06/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |